Key result
Sodium hyaluronate combined with celecoxib significantly reduced VAS scores (SMD -1.61; 95% CI -2.25 to -0.98; P<0.00001) and improved clinical efficiency in knee osteoarthritis.
Why the study?
Due to high costs, surgical complications, and contraindications associated with joint replacement for knee osteoarthritis, conservative pharmacological treatment remains essential.
Does sodium hyaluronate combined with celecoxib improve pain and clinical outcomes in patients with knee osteoarthritis?
Meta-Analysis (n=2,339)
Does sodium hyaluronate combined with celecoxib improve pain and clinical outcomes in patients with knee osteoarthritis?
Standardized Mean Difference: -1.61 (95% CI -2.25–-0.98)
p-value: p=<0.00001
The combination of sodium hyaluronate and celecoxib is safe and effective for treating knee osteoarthritis, significantly improving pain and clinical scores while reducing adverse effects.
Supports combination therapy for improved pain and function in knee OA; confirms efficacy and safety across 9 RCTs.
Due to the large cost of joint replacement for surgical treatment of knee osteoarthritis, there are many complications in elderly patients, and there are many contraindications to surgery, and conservative treatment is still based on drugs. To further evaluate the efficacy and safety of sodium hyaluronate combined with celecoxib for the treatment of osteoarthritis of the knee. In total, 202 studies were screened, with a final selection of 9 RCTs involving 2339 participants; of these, 9 RCTs were included in the final meta-analysis. Treatment group reduces VAS (SMD = −1.61; 95 % CI [−2.25, −0.98]; I2 = 95 %; P < 0.00001) and adverse reactions (OR = 0.45; 95 % CI [0.22,0.94]; I2 = 0 %; P < 0.33); Meanwhile, improving Lysholm knee scores (SMD = 0.19; 95 % CI [−0.06, −0.44]; I2 = 76 %; P = 0.0004) and Clinical efficiency (OR = 0.31; 95 % CI [0.19,0.50]; I2 = 0 %; P < 0.00001). All indicators were superior to the control group. Our primary findings suggest that KOA treatment with celecoxib combined with sodium hyaluronate reduces VAS, while improving Lysholm scores and Clinical efficiency. In addition, we found that celecoxib combined with sodium hyaluronate treatment had fewer adverse effects than the control group, indicating that the combination is safe and effective in the treatment of KOA.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2023) conducted a meta-analysis in Knee osteoarthritis (n=2,339). Sodium hyaluronate combined with celecoxib vs. Control group was evaluated on VAS (Visual Analog Scale) score (SMD -1.61, 95% CI -2.25, -0.98, p=<0.00001). Sodium hyaluronate combined with celecoxib significantly reduced VAS scores (SMD -1.61; 95% CI -2.25 to -0.98; P<0.00001) and improved clinical efficiency in knee osteoarthritis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: